Trikafta, the first triple combination therapy available, was approved this week by the FDA for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This is estimated to be 90% of the CF population, and seems like a win for patients and the maker.
Click here to check out the WebMD article from Tuesday or here for today’s article from BioPharma Dive. You can also click here to see the FDA News Release from October 21, 2019.